Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Sorafenib 29Nivolumab 15pembrolizumab 12Radiosurgery 9Bevacizumab 9atezolizumab 7regorafenib 5Radiotherapy 5Fluorouracil 5Doxorubicin 5lenvatinib 4Sunitinib 4Oxaliplatin 4Ipilimumab 4Gemcitabine 4Ethiodized Oil 4Erlotinib Hydrochloride 4Capecitabine 4TLC 388 3Radiofrequency Ablation 3Leucovorin 3Everolimus 3Cisplatin 3Blood Specimen Collection 3toripalimab 2phosphomannopentaose sulfate 2durvalumab 2cediranib 2avelumab 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Hepatocellular × MK 2206 × Clear all
NCT01239355 2015-10-05

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 2 Terminated
15 enrolled 6 charts
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡